Dova Pharma's bet on Eisai castoff spells gold as Sobi spends millions to acquire it
In 2016, Dova Pharmaceuticals paid Japan’s Eisai a paltry $5 million upfront for the rights to the Phase III-ready avatrombopag. The following year, the Durham …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
